{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:14:15Z","timestamp":1793297655910,"version":"4.5.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"name":"Resverlogix Corporation"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>\n                      CKD and type 2 diabetes mellitus interact to increase the risk of major adverse cardiovascular events (\n                      <jats:italic toggle=\"yes\">i.e.<\/jats:italic>\n                      , cardiovascular death, nonfatal myocardial infarction, or stroke) and congestive heart failure. A maladaptive epigenetic response may be a cardiovascular risk driver and amenable to modification with apabetalone, a selective modulator of the bromodomain and extraterminal domain transcription system. We examined this question in a prespecified analysis of BETonMACE, a phase 3 trial.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>\n                      BETonMACE was an event-driven, randomized, double-blind, placebo-controlled trial comparing effects of apabetalone versus placebo on major adverse cardiovascular events and heart failure hospitalizations in 2425 participants with type 2 diabetes and a recent acute coronary syndrome, including 288 participants with CKD with eGFR &lt;60 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      at baseline. The primary end point in BETonMACE was the time to the first major adverse cardiovascular event, with a secondary end point of time to hospitalization for heart failure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median follow-up was 27 months (interquartile range, 20\u201332 months). In participants with CKD, apabetalone compared with placebo was associated with fewer major adverse cardiovascular events (13 events in 124 patients [11%] versus 35 events in 164 patients [21%]; hazard ratio, 0.50; 95% confidence interval, 0.26 to 0.96) and fewer heart failure\u2013related hospitalizations (three hospitalizations in 124 patients [3%] versus 14 hospitalizations in 164 patients [9%]; hazard ratio, 0.48; 95% confidence interval, 0.26 to 0.86). In the non-CKD group, the corresponding hazard ratio values were 0.96 (95% confidence interval, 0.74 to 1.24) for major adverse cardiovascular events, and 0.76 (95% confidence interval, 0.46 to 1.27) for heart failure\u2013related hospitalization. Interaction of CKD on treatment effect was\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.03 for major adverse cardiovascular events, and\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.12 for heart failure\u2013related hospitalization. Participants with CKD showed similar numbers of adverse events, regardless of randomization to apabetalone or placebo (119 [73%] versus 88 [71%] patients), and there were fewer serious adverse events (29% versus 43%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.02) in the apabetalone group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Apabetalone may reduce the incidence of major adverse cardiovascular events in patients with CKD and type 2 diabetes who have a high burden of cardiovascular disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.16751020","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T13:30:44Z","timestamp":1619530244000},"page":"705-716","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":61,"title":["Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome"],"prefix":"10.2215","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8666-0725","authenticated-orcid":false,"given":"Kamyar","family":"Kalantar-Zadeh","sequence":"first","affiliation":[{"name":"Division of Nephrology, Hypertension and Kidney Transplantation, University of California Irvine School of Medicine, Orange, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Monash Cardiovascular Research Centre, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin A.","family":"Buhr","sequence":"additional","affiliation":[{"name":"Statistical Data Analysis Center, University of Wisconsin, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry N.","family":"Ginsberg","sequence":"additional","affiliation":[{"name":"Vagelos College of Physicians and Surgeons, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan O.","family":"Johansson","sequence":"additional","affiliation":[{"name":"Resverlogix Corporation, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Kulikowski","sequence":"additional","affiliation":[{"name":"Resverlogix Corporation, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Lebioda","sequence":"additional","affiliation":[{"name":"Resverlogix Corporation, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[{"name":"CGH Medical Center Sterling, Sterling, Illinois"},{"name":"Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Wong","sequence":"additional","affiliation":[{"name":"Resverlogix Corporation, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sweeney","sequence":"additional","affiliation":[{"name":"Resverlogix Corporation, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[{"name":"Imperial Centre for Cardiovascular Disease Prevention, Imperial College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the BETonMACE Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,5,8]]},"reference":[{"key":"B3-20241015","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nrneph.2017.60","article-title":"Alkaline phosphatase: A novel treatment target for cardiovascular disease in CKD","volume":"13","author":"Haarhaus","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"B4-20241015","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S2213-8587(14)70246-3","article-title":"Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): A randomised clinical trial","volume":"3","author":"de Zeeuw","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B5-20241015","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"B6-20241015","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"B7-20241015","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B8-20241015","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/20974","article-title":"Structure and ligand of a histone acetyltransferase bromodomain","volume":"399","author":"Dhalluin","year":"1999","journal-title":"Nature"},{"key":"B9-20241015","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0014-5793(01)03309-9","article-title":"Bromodomain: An acetyl-lysine binding domain","volume":"513","author":"Zeng","year":"2002","journal-title":"FEBS Lett"},{"key":"B10-20241015","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nsmb.3228","article-title":"BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin","volume":"23","author":"Devaiah","year":"2016","journal-title":"Nat Struct Mol Biol"},{"key":"B11-20241015","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/nsmb.2912","article-title":"BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones","volume":"21","author":"Kanno","year":"2014","journal-title":"Nat Struct Mol Biol"},{"key":"B12-20241015","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.molcel.2014.08.024","article-title":"NF-\u03baB directs dynamic super enhancer formation in inflammation and atherogenesis","volume":"56","author":"Brown","year":"2014","journal-title":"Mol Cell"},{"key":"B13-20241015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/biomedicines6010016","article-title":"BET family protein BRD4: An emerging actor in NF\u03baB signaling in inflammation and cancer","volume":"6","author":"Hajmirza","year":"2018","journal-title":"Biomedicines"},{"key":"B14-20241015","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ekir.2017.12.001","article-title":"Benefit of apabetalone on plasma proteins in renal disease","volume":"3","author":"Wasiak","year":"2017","journal-title":"Kidney Int Rep"},{"key":"B15-20241015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.atherosclerosis.2018.11.002","article-title":"Apabetalone downregulates factors and pathways associated with vascular calcification","volume":"280","author":"Gilham","year":"2019","journal-title":"Atherosclerosis"},{"key":"B16-20241015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.atherosclerosis.2019.09.002","article-title":"Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease","volume":"290","author":"Haarhaus","year":"2019","journal-title":"Atherosclerosis"},{"key":"B17-20241015","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ahj.2019.08.001","article-title":"Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial","volume":"217","author":"Ray","year":"2019","journal-title":"Am Heart J"},{"key":"B19-20241015","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1523-1755.2004.00733.x","article-title":"Chronic kidney disease: The distribution of health care dollars","volume":"66","author":"St Peter","year":"2004","journal-title":"Kidney Int"},{"key":"B20-20241015","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.jacc.2012.11.071","article-title":"Outcomes associated with microalbuminuria: Effect modification by chronic kidney disease","volume":"61","author":"Kovesdy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B21-20241015","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jacc.2014.04.065","article-title":"Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population","volume":"64","author":"Sim","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B22-20241015","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/sj.ki.5000417","article-title":"Traditional and emerging cardiovascular and renal risk factors: An epidemiologic perspective","volume":"70","author":"Zoccali","year":"2006","journal-title":"Kidney Int"},{"key":"B23-20241015","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/ndt\/gfy009","article-title":"Targeting epigenetic DNA and histone modifications to treat kidney disease","volume":"33","author":"Fontecha-Barriuso","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"B24-20241015","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1161\/CIRCULATIONAHA.109.851873","article-title":"Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality","volume":"120","author":"Tonelli","year":"2009","journal-title":"Circulation"},{"key":"B25-20241015","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1159\/000488257","article-title":"Apabetalone mediated epigenetic modulation is associated with favorable kidney function and alkaline phosphatase profile in patients with chronic kidney disease","volume":"43","author":"Kulikowski","year":"2018","journal-title":"Kidney Blood Press Res"},{"key":"B26-20241015","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/HYPERTENSIONAHA.115.06117","article-title":"Serum alkaline phosphatase negatively affects endothelium-dependent vasodilation in na\u00efve hypertensive patients","volume":"66","author":"Perticone","year":"2015","journal-title":"Hypertension"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.16751020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:43:59Z","timestamp":1786369439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.16751020"}},"subtitle":["Results from the BETonMACE Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.16751020","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"2020-10-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}